SANNZ logo

Santhera Pharmaceuticals Holding BATS-CHIXE:SANNZ Stock Report

Last Price

CHF 10.44

Market Cap

CHF 126.6m

7D

8.9%

1Y

5.1%

Updated

23 Dec, 2024

Data

Company Financials +

Santhera Pharmaceuticals Holding AG

BATS-CHIXE:SANNZ Stock Report

Market Cap: CHF 126.6m

SANNZ Stock Overview

A specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. More details

SANNZ fundamental analysis
Snowflake Score
Valuation5/6
Future Growth6/6
Past Performance3/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Santhera Pharmaceuticals Holding AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Santhera Pharmaceuticals Holding
Historical stock prices
Current Share PriceCHF 10.44
52 Week HighCHF 11.30
52 Week LowCHF 7.69
Beta0.14
1 Month Change29.29%
3 Month Change16.13%
1 Year Change5.14%
3 Year Changen/a
5 Year Changen/a
Change since IPO394.79%

Recent News & Updates

Recent updates

Shareholder Returns

SANNZGB BiotechsGB Market
7D8.9%-5.1%-2.2%
1Y5.1%-24.5%2.4%

Return vs Industry: SANNZ exceeded the UK Biotechs industry which returned -24.5% over the past year.

Return vs Market: SANNZ exceeded the UK Market which returned 2.4% over the past year.

Price Volatility

Is SANNZ's price volatile compared to industry and market?
SANNZ volatility
SANNZ Average Weekly Movement6.2%
Biotechs Industry Average Movement7.0%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.5%
10% least volatile stocks in GB Market2.6%

Stable Share Price: SANNZ has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: SANNZ's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200445Dario Eklundwww.santhera.com

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases.

Santhera Pharmaceuticals Holding AG Fundamentals Summary

How do Santhera Pharmaceuticals Holding's earnings and revenue compare to its market cap?
SANNZ fundamental statistics
Market capCHF 126.63m
Earnings (TTM)CHF 62.86m
Revenue (TTM)CHF 113.59m

2.0x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SANNZ income statement (TTM)
RevenueCHF 113.59m
Cost of RevenueCHF 6.52m
Gross ProfitCHF 107.07m
Other ExpensesCHF 44.21m
EarningsCHF 62.86m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)5.19
Gross Margin94.26%
Net Profit Margin55.34%
Debt/Equity Ratio49.2%

How did SANNZ perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:10
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santhera Pharmaceuticals Holding AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurizio BernasconiBank am Bellevue
Silvia SchanzBank Vontobel AG
Barbora BlahaCredit Suisse